DailyIQ
Last updated4 minutes ago

BMRN·BioMarin Pharmaceutical Inc.

$55.16
+0.78 (+1.43%)
Overnight$55.25+0.09 (+0.16%)
High
$55.56
Open
$54.76
Market Cap
10.57B
52W High
$70.98
Low
$54.37
P. Close
$55.16
P/E
144.86
52W Low
$49.25
Fwd P/E
8.30
DailyIQ Est.
$97.66
Inst. Ownership
45.1%
Short Interest
5.93%
Days to Cover
5.5
NewEarnings release, scored · filed Aug 6, 2026Guidance raised · 56 lines scoredSee the breakdown
Technical Score (1D)
65
BULLISH
News Sentiment
58
BULLISH
On Oct 13, analysts noted that BioMarin Pharmaceutical Inc. (BMRN) continues to trade at a discount to its forward earnings, reflecting a value-oriented stance. The company’s robust margins and healthy cash flow underpin this valuation. Ongoing health and growth risks temper enthusiasm for the stock. The assessment suggests that BMRN remains a solid investment opportunity for value-focused investors. No imminent upside catalyst was identified.
LOW TARGET
$60 +8.8%
2 analysts
MEAN TARGET
$92 +66.2%
17 analysts
HIGH TARGET
$124 +124.9%
18 analysts
PRICE RANGE
$60.00 - $124.00
SB / B / H / S / SS
10/17/8/1/1
DAILYIQ EST.
$97.66 (+77.1%)
Bought (1Y)
0 shares
$0
Sold (1Y)
21,643 shares
$1.4M
Friberg Gregory REVP, Chief R&D Officer
Tax Withholding4,086 shares2026-09-30
Plenge Robert M-
Award/Grant6,140 shares2026-09-10
Davis George EricEVP, Chief Legal Officer
Sell17,557 shares2026-09-02
ANDERSON ELIZABETH M-
Award/Grant7,490 shares2026-06-02
Bodem Barbara W.-
Award/Grant7,490 shares2026-06-02
85/ 100
Bullish
Overall: Bullish
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Net Margin
10.8%
Revenue CAGR
15.1%
Current Ratio
5.21x
Return on Equity
5.7%

EPS

EstBeatMiss
$0.70$0.82$0.94$1.07$1.19Q1'25Q1'26Q3'26
QtrEstActual+/−
Q3'26$0.95 - -
Q1'26$0.81$0.76-6.2%
Q1'25$0.95$1.13+18.6%

Revenue

EstBeatMiss
$703M$794M$885M$976M$1.1BQ1'25Q1'26Q3'26
QtrEstActual+/−
Q3'26$1.0B - -
Q1'26$771M$766M-0.6%
Q1'25 - $745M -

Market Data

BMRN Stock Snapshot

BULLISH65/100
$55.25+$0.09 (0.2%)
Market cap
10.57B
P/E ratio
144.9
Day range
$54.37 – $55.56
News sentiment
58/100 · Neutral
Analyst target
$91.62 (+65.8%)
Consensus
Buy · 37 analysts
52-week range+12.2% off low · -22.2% from high
$49.25$70.98
Price $55.25 DailyIQ Est. $97.66

The signal on BMRN is bullish: price action is confirming the underlying trend, not fighting it. Institutional coverage is thorough here, so shifts in analyst expectations show up in price quickly.

Behaviour On Record

What BMRN's own history says about today's numbers

Realized volatility (21d)
23.8% 17th pct
Below its peak
-63.0%
vs 200-day average
-5.9%
Up days (1y)
46%

BioMarin Pharmaceutical Inc. is currently running 23.8% annualised volatility over the last 21 sessions. Measured against BMRN's own 13 years of daily returns rather than a market-wide average, that is the 17th percentile — unusually subdued by its own history, against a typical reading of 32.1%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

BMRN is trading -63.0% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -34.1%, and the deepest was -44.9% in 2020. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.

Price sits -5.9% from its 200-day moving average. Against every other day in its history, that gap ranks at the 35th percentile — close to the gap it normally carries. Over the past year BMRN closed higher on 46% of sessions, and it is currently 1 session into a rising streak.

On October specifically: over 14 years of records, BMRN finished the month higher 4 of 14 times, with a median return of -4.0% and an average of -1.5%. Its strongest month historically has been November at +5.4% on average, its weakest September at -6.1%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: BMRN has opened more than 2% away from the prior close in 199 of 3,267 sessions (6.1% of the time), with the largest gaps running +9.3% and -10.5%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

All figures computed from 3,268 daily closes between 2013-10-15 and 2026-10-14, split-adjusted, recomputed daily. Percentiles are against BMRN's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of BMRN's sector?

BioMarin Pharmaceutical Inc. sits in the Health Care sector, currently ranked 2nd of 12 GICS sectors by relative-strength rotation score (leading). Within its narrower Biotechnology industry group, BMRN ranks 9th of 15 tracked industries, improving.

Sector rank
#2 of 12
Sector state
Leading
Sector rotation score
82
Industry rank
#9 of 15

Options Market

What is the options market pricing for BMRN?

CallsPuts

For BioMarin Pharmaceutical Inc.'s nearest expiry (2026-10-16, 1 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.42), with at-the-money implied volatility around 60.2%. The options market is pricing roughly a ±2.9% move by that expiry — a range of about $53.66–$56.91.

Put/call ratio (2026-10-16)
0.42
ATM implied volatility
60.2%
Total open interest
6,070
Expected move by 2026-10-16
±2.9% ($53.66–$56.91)

Analyst Rating Changes

Are analysts turning bullish or bearish on BMRN?

Barclays most recently reiterated its rating on BioMarin Pharmaceutical Inc. to Overweight on Oct 14, 2026 with a price target of $114 (from $111). Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.

Latest action
Barclays — Overweight
90-day upgrades
0
90-day downgrades
0
Net rating momentum
0
DateFirmActionRatingPrice target
Oct 14, 2026BarclaysMaintainedOverweight$111 → $114
Sep 10, 2026HC Wainwright & Co.ReiteratedNeutral$60
Sep 1, 2026Piper SandlerMaintainedOverweight$88 → $90
Aug 31, 2026JefferiesMaintainedBuy$104 → $105
Aug 31, 2026HC Wainwright & Co.MaintainedNeutral$59 → $60
Aug 19, 2026BMO CapitalInitiatedOutperform$98
Aug 18, 2026HC Wainwright & Co.MaintainedNeutral$60 → $59
Aug 17, 2026Piper SandlerMaintainedOverweight$82 → $88
Aug 17, 2026BarclaysMaintainedOverweight$105 → $111
Aug 10, 2026Canaccord GenuityMaintainedBuy$111 → $114
Aug 7, 2026Morgan StanleyMaintainedOverweight$119 → $124
Aug 7, 2026OppenheimerMaintainedOutperform$95 → $97

Earnings Release, Scored

What did BioMarin Pharmaceutical Inc.'s latest earnings release say?

Filed Aug 6, 2026 · SEC Form 8-K, Exhibit 99

Guidance raised
Tone70.0/ 100
Hedging words0.96per 100 words

Most important lines

  1. 1

    “Strong global demand led us to increase full-year VOXZOGO revenue guidance to at least $1 billion in 2026.

    Guidance raised
  2. 2

    Strong U.S. and global demand led to increased full-year 2026 VOXZOGO revenue guidance to a low end of $1 billion.

    Guidance raised
  3. 3

    The company is targeting gross leverage below 2.5 times by mid-year 2027, an acceleration by approximately one year of prior timeline guidance provided at deal announcement, supported by profitability growth of the combined company.

    Guidance raised

ETF holders

ETFs holding BMRN

News Sentiment Analysis

Sentiment gathered from recent headlines

58/100
Strong NegativeNeutralStrong Positive
MODERATELY BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
On October 13, analysts noted that BioMarin (BMRN) continues to trade at a discount to its forward earnings, reflecting a value-oriented stance. The company’s robust margins and healthy cash flow underpin this valuation, while ongoing health and growth risks temper enthusiasm. The assessment suggests that BMRN remains a solid investment opportunity for value-focused investors, though it does not signal an imminent upside catalyst.
What did this article say?
BioMarin Pharmaceutical Inc. announced it would present new data from 13 studies at the American Society for Bone and Mineral Research 2026 Annual Meeting. The presentation included results from VOXZOGO® (vosoritide) trials in children with achondroplasia and hypochondroplasia, focusing on foramen magnum and craniocervical junction growth. Additionally, the company planned to share data on the investigational long‑acting therapy BMN 333. The disclosure signals ongoing clinical development but does not indicate a material shift in guidance or market outlook.
What did this article say?
On October 8, BioMarin Pharmaceutical (BMRN) released updated clinical data, presenting five‑year outcomes for its POMBILITI and OPFOLDA therapies in late‑onset Pompe disease. The company also disclosed early‑stage results from its nivudirsen program, aimed at expanding its gene‑therapy portfolio. These data were delivered after a period of share price weakness, suggesting a potential turnaround for the stock. The announcement is expected to reinforce investor confidence in BMRN’s pipeline and could positively influence short‑term trading activity.
What did this article say?
BioMarin Pharmaceutical disclosed that the acquisition of Alesta Therapeutics will trigger a $283 million pre‑tax charge, reducing Q3 adjusted earnings per share by $1.50. The company projects a similar $320 million charge for 2026, translating to a $1.55 hit on annual adjusted EPS. The filing indicates the impact will be material and is expected to be priced into the market.
What did this article say?
BioMarin Pharmaceutical announced that it expects $283 million in pre‑tax charges for Q3 related to the acquisition of Alesta, which will reduce GAAP and non‑GAAP diluted earnings per share by $1.5. The company projects total pre‑tax charges of $320 million for FY26, translating to a $1.55 adverse effect on diluted EPS for the year. These significant one‑time costs are expected to materially depress the company’s earnings outlook for the remainder of the year.
What did this article say?
BioMarin Pharmaceutical Inc. announced on October 5, 2026 that Cara Bauer, Ph.D., would become Executive Vice President and Chief People Officer, succeeding retiring Amy Wireman. Bauer brings more than 25 years of human resources experience from biotechnology, technology, and entertainment companies, including Kyverna Therapeutics, Kite, and Netflix. Her appointment is intended to strengthen BioMarin’s HR organization amid ongoing growth and change. The move signals the company’s focus on building a robust talent strategy to support its pipeline and operational objectives. No immediate financial or strategic impact was disclosed beyond the leadership transition.
What did this article say?
BioMarin announced that the five‑year open‑label extension of its PROPEL study demonstrated sustained motor function and stable pulmonary outcomes for patients with late‑onset Pompe disease. The data, presented at the World Muscle Society Congress, included 82 participants who continued therapy from baseline through year five. The results reinforce the long‑term efficacy and safety profile of POMBILITI® combined with OPFOLDA®, supporting the treatment’s continued use in both ERT‑experienced and naïve patients.
What did this article say?
BioMarin Pharmaceutical Inc. (BMRN) presented new efficacy data for its combination therapy POMBILITI® and OPFOLDA® in late‑onset Pompe disease at the 31st Annual Congress of the World Muscle Society. The study showed improved clinical outcomes without any new safety signals. The data reinforce the therapeutic potential of the drug pair and support ongoing development plans.
What did this article say?
TCW’s second‑quarter 2026 investor letter named BioMarin Pharmaceutical (BMRN) as one of its top holdings, citing the company’s cash‑generative profile and resilient business model. The letter noted that BMRN’s inclusion aligns with the fund’s focus on robust earnings and stable cash flow amid market volatility. TCW highlighted BMRN alongside other high‑quality mid‑cap names, underscoring its confidence in the company’s long‑term value proposition. The commentary came as broader equity markets rebounded from Q1 lows, with the S&P 500 reaching record highs.

Technical Analysis

Real-time indicators across multiple timeframes

65
BULLISH
Momentum rank against about 1,000 stocks and ETFs for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $5.00B combined position · 15 adding, 10 trimming, 0 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
BlackRock, Inc.▲ Buy20,445,21210.52%$1.17B2026-08-07
Vanguard Group Inc▼ Sell18,127,8479.32%$1.08B2026-01-29
Norges Bank▲ Buy8,207,9544.22%$469.66M2026-08-12
Viking Global Investors LP▲ Buy7,616,5633.92%$435.82M2026-08-14
AQR Capital Management LLC▼ Sell5,699,5412.93%$322.54M2026-08-14
FMR LLC (Fidelity)▲ Buy4,822,8932.48%$275.97M2026-08-13
Geode Capital Management, LLC▲ Buy3,911,7942.01%$223.89M2026-08-12
Capital Research Global Investors▲ Buy3,504,3871.80%$200.52M2026-08-12
Millennium Management LLC▼ Sell2,071,8161.07%$118.55M2026-08-14
Northern Trust Corp▼ Sell1,558,1040.80%$89.15M2026-08-13
Morgan Stanley▲ Buy1,504,9890.77%$86.12M2026-08-13
Goldman Sachs Group Inc▲ Buy1,201,9770.62%$68.78M2026-08-14
Citadel Advisors LLC▼ Sell1,122,4080.58%$64.22M2026-09-02
Balyasny Asset Management L.P.▼ Sell1,054,6130.54%$60.34M2026-08-14
Janus Henderson Group plc▲ Buy857,0100.44%$48.41M2026-05-18
Loomis Sayles & Co L P▼ Sell713,6570.37%$40.84M2026-08-14
JPMorgan Chase & Co▲ Buy694,5500.36%$40.57M2026-08-12
Palo Alto Investors LP▼ Sell682,7770.35%$39.07M2026-08-19
Bank of America Corp▼ Sell663,1630.34%$37.95M2026-08-14
Invesco Ltd.▲ Buy494,6040.25%$28.30M2026-08-14
Renaissance Technologies LLC▼ Sell451,8710.23%$25.86M2026-08-13
Prudential Financial Inc▲ Buy392,8110.20%$22.48M2026-08-12
Man Group plc▲ Buy367,9810.19%$21.06M2026-08-14
AllianceBernstein L.P.▲ Buy283,4000.15%$16.01M2026-08-14
Bridgewater Associates, LP▲ Buy274,9110.14%$15.73M2026-08-14
Q2 2026 flow:4.87M sh bought ($278.89M)7.49M sh sold ($427.42M)net -2.62M sh (−$148.53M)